Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12356 clinical trials
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

measurable disease
peripheral t-cell lymphoma
tucidinostat
pet/ct scan
chidamide
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CN1

This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.

solid tumour
lymphoma
b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

oximetry
lymphoblastic leukemia
cancer chemotherapy
flow cytometry
lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

oximetry
lymphoblastic leukemia
ejection fraction
autologous hematopoietic stem cell transplant
lymphoblastic lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

high-grade lymphoma
rituximab
creatinine clearance rate
18f-fdg
granulocyte colony stimulating factor
  • 0 views
  • 19 Feb, 2024
  • 1 location
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

rituximab
immunochemotherapy
monoclonal protein
rituximab fludarabine
b-cell lymphoma refractory
  • 0 views
  • 19 Feb, 2024
  • 3 locations
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

lymphoma
diffuse large b-cell lymphoma
primary cns lymphoma
b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 5 locations
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

recurrent disease
adult acute lymphocytic leukemia
lupus
leukapheresis
ejection fraction
  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

recurrent disease
excisional biopsy
hair thinning
cutaneous t-cell lymphoma
multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in …

anaplastic large cell lymphoma
lenalidomide
peripheral t-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location